Case-control study suggests a favorable impact of TEL rearrangement in patients with B-lineage acute lymphoblastic leukemia treated with antimetabolite-based therapy: A Pediatric Oncology Group study

Blood

Volumn 89, Issue 4, 1997, Pages 1143-1146

  Rubnitz, Jeffrey E ^b   Shuster, Jonathan J ^b   Land, Vita J ^b   Link, Michael P ^b   Pullen, D Jeanette ^b   Camitta, Bruce M ^b   Pui, Ching Hon ^b   Downing, James R ^b   Behm, Frederick G ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CYTARABINE; HYDROCORTISONE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; FEMALE; GENE REARRANGEMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0031055374     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.4.1143     Document Type: Article

References (30)

1. Pui C-H: Childhood leukemias. N Engl J Med 332:1618, 1995
2. Crist WM, Carroll AJ, Shuster JJ, Behm FG, Whitehead M, Vietti TJ, Look AT, Mahoney D, Ragab A, Pullen DJ, Land VJ: Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the 1(1; 19)(q23;p13): A Pediatric Oncology Group study. Blood 76:117, 1990
3. Fletcher JA, Kimball VM, Lynch E, Donnelly M, Pavelka K, Gelber RD, Tantravahi R, Sallan SE: Prognostic implications of cytogenetic studies in an intensively treated group of children with acute lymphoblastic leukemia. Blood 74:2130, 1989
4. Crist W, Carroll A, Shuster J, Jackson J, Head D, Borowitz M, Behm F, Link M, Steuber P, Ragab A, Hirt A, Brock B, Land V, Pullen J: Philadelphia chromosome positive childhood acute lymphoblastic leukemia: Clinical and cytogenetic characteristics and treatment outcome. A Pediatric Oncology Group study. Blood 76:489, 1990
5. Fletcher JA, Lynch EA, Kimball VM, Donnelly M, Tantravahi R, Sallan SE: Translocation (9; 22) is associated with extremely poor prognosis in intensively treated children with acute lymphoblastic leukemia. Blood 77:435, 1991
6. Rubnitz JE, Link MP, Shuster JJ, Carroll AJ, Hakami N, Frankel LS, Pullen DJ, Cleary ML: Frequency and prognostic significance of HRX rearrangements in infant acute lymphoblastic leukemia: A Pediatric Oncology Group study. Blood 84:570, 1994
7. Raimondi SC: Current status of cytogenetic research in childhood acute lymphoblastic leukemia. Blood 70:2237, 1993
8. Crist WM, Cleary ML, Grossi CE, Prasthofer E, Heggie GD, Omurra GA, Carroll AJ, Link MP, Sklar J: Acute leukemias associated with the 4; 11 chromosome translocation have rearranged immunoglobulin heavy chain genes. Blood 66:33, 1985
9. Privitera E, Kamps MP, Hayashi Y, Inaba T, Shapiro LH, Raimondi SC, Behm F, Hendershot L, Carroll AJ, Baltimore D, Look AT: Different molecular consequences of the 1;19 chromosomal translocation in childhood B-cell precursor acute lymphoblastic leukemia. Blood 79:1781, 1992
10. Pui C-H, Crist WM: Biology and treatment of acute lymphoblastic leukemia. J Pediatr 124:491, 1994
11. Rubnitz JE, Behm FG, Downing JR: 11q23 rearrangements in acute leukemia. Leukemia 10:74, 1996
12. Trueworthy R, Shuster J, Look T, Crist W, Borowitz M, Carroll A, Frankel L, Harris M, Wagner H, Haggard M, Mosijczuk A, Pullen J, Steuber P, Land V: Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: A Pediatric Oncology Group study. J Clin Oncol 10:606, 1992
13. Harris MB, Shuster JJ, Carroll A, Look AT, Borowitz MJ, Crist WM, Nitschke R, Pullen J, Steuber CP, Land VJ: Trisomy of leukemic cell chromosomes 4 and 10 identifies children with B-progentior cell acute lymphoblastic leukemia with a very low risk of treatment failure: A Pediatric Oncology Group study. Blood 79:3316, 1992
14. Shurtleff SA, Bujis A, Behm FG, Rubnitz JE, Raimondi SC, Hancock ML, Chan GC-F, Pui C-H, Grosveld G, Downing JR: TEL/ AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia 9:1985, 1995
15. Romana SP, Poirel H, Leconiat M, Flexor M-A, Mauchauffe M, Jonveaux P, Macintyre EA, Berger R, Bernard OA: High frequency of t( 12;21) in childhood B-lineage acute lymphoblastic leukemia. Blood 86:4263, 1995
16. Goluh TR, Barker GF, Bohlunder SK, Hieben SW, Ward DC, Bray-Ward P, Morgan E, Raimondi SC, Rowley JD, Gilliland DG: Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci USA 92:4917, 1995
17. Romans SP, Mauchauffe M, Le Coniat M, Chumakov I, Le Paslier D, Berger R, Bernard OA: The t(12:21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion. Blood 85:3662, 1995
18. Rubnitz JE, Pui C-H, Shurtleff SA, Raimondi SC, Evans WE, Head DR, Crist WM, Rivera GK, Hancock ML, Boyett JM, Buijs A, Grosveld G, Downing JR, Behm FG: TEL gene rearrangement in acute lymphoblastic leukemia: A new genetic marker with prognostic significance. J Clin Oncol (in press)
19. Rivera GK, Raimondi SC, Hancock ML, Behm FG, Pui C-H, Abromowitch M, Mirro J Jr, Ochs JS, Look AT, Williams DL, Murphy SB, Dahl GV, Kalwinsky DK, Evans WE, Kun LE, Simone JV, Crist WM: Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Lancet 337:61, 1991
20. Evans WE. Rodman J, Relling MV, Crom WR, Rivera GK, Crist WM, Pui C-H: Individualized dosages of chemotherapy as a strategy to improve response for acute lymphocytic leukemia. Semin Hematol 28:15, 1991 (suppl 4)
21. Chambost H, Michel G, Thuret I, Toiron Y, Brunet C, Capodano AM, Sainty D, Maraninchi D, Gabert J: TEL/AML1 transcript in childhood acute lymphoblastic leukemia: A new candidate for minimal residual disease study rather than a new prognosis factor? Br J Haematol 93:55, 1996 (suppl 2)
22. Breslow NE, Day NE: Statistical Methods in Cancer Research, Vo1 1 : The Analysis of Case-Control Studies. Lyon, France, International Agency for Research on Cancer, 1980
23. Shuster JJ: The cross-product estimator in matched case-control studies. Biometrika 73:212, 1986
24. Mantel N, Haenszel S: Statistical aspects of the analysis of data from the retrospective study of disease. J Natl Cancer Inst 22:719, 1959
25. Kaplan E, Meier P: Nonparametric estimation from incomplete observatons. J Am Stat Assoc 53:457, 1958
26. Pui C-H, Behm FG, Raimondi SC, Dodge RK, George SL, Rivera GK, Mirro J Jr, Kalwinsky DK, Dahl GV, Murphy SB, Crist WM, Williams DL: Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med 321:136, 1989
27. Pui C-H, Ribeiro RC, Hancock ML, Rivera GK, Evans WE, Raimondi SC, Head DR, Behm FG, Mahmoud HH, Sandlund JT, Crist WM: Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 325:1682, 1991
28. Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, Sanders SP, Orav EJ, Gelber RD, Colan SD: Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 332:1738, 1995
29. Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, Gelber R, Heerema N, Korn EL, Link M, Murphy S, Pui C-H, Pullen J, Reaman G, Sallan S, Sather H, Shuster J, Simon R, Trigg M, Tubergen D, Uckun F, Ungerleider R: Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 14:18, 1996
30. Hiebert SW, Sun W-H, Davis JN, Golub T, Shurtleff S, Buijs A, Downing JR, Grosveld G, Roussel M, Gilliland DG, Lenny N, Meyers S: The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription. Mol Cell Biol 16:1349, 1996